Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
GH Research PLC (GHRS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: GHRS (1-star) is a SELL. SELL since 3 days. Profits (-0.40%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $33.14
1 Year Target Price $33.14
| 5 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 69.01% | Avg. Invested days 45 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 771.65M USD | Price to earnings Ratio - | 1Y Target Price 33.14 |
Price to earnings Ratio - | 1Y Target Price 33.14 | ||
Volume (30-day avg) 8 | Beta 0.97 | 52 Weeks Range 6.00 - 20.50 | Updated Date 06/30/2025 |
52 Weeks Range 6.00 - 20.50 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.79 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -11.97% | Return on Equity (TTM) -16.2% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 480336379 | Price to Sales(TTM) - |
Enterprise Value 480336379 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -11.97 | Shares Outstanding 62029400 | Shares Floating 19743559 |
Shares Outstanding 62029400 | Shares Floating 19743559 | ||
Percent Insiders 33.88 | Percent Institutions 68.88 |
Analyst Ratings
Rating 3 | Target Price 33.14 | Buy 3 | Strong Buy 5 |
Buy 3 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
GH Research PLC
Company Overview
History and Background
GH Research PLC, founded in 2019, is a biopharmaceutical company focused on developing novel therapies for mental health disorders using 5-MeO-DMT. It went public in 2021.
Core Business Areas
- GH001: A proprietary formulation of 5-MeO-DMT administered via inhalation for Treatment-Resistant Depression (TRD).
- GH002: An intravenous formulation of 5-MeO-DMT being explored for potential use in other mental health indications.
Leadership and Structure
The company is led by CEO Mike Petrone. The organizational structure includes research and development, clinical operations, and business development departments.
Top Products and Market Share
Key Offerings
- GH001: A proprietary inhaled formulation of 5-MeO-DMT being developed for Treatment-Resistant Depression (TRD). Market share is currently 0% as the product is still in clinical trials. The primary competitors include companies developing psilocybin-based therapies, such as COMPASS Pathways and Atai Life Sciences.
- GH002: An intravenous formulation of 5-MeO-DMT in clinical trials. Competitors are similar to GH001, focusing on psychedelic-assisted therapies.
Market Dynamics
Industry Overview
The industry is focused on developing novel treatments for mental health disorders, including psychedelic-assisted therapies. There is growing interest and investment in this area, driven by the limitations of existing treatments.
Positioning
GH Research PLC is positioned as a leader in developing 5-MeO-DMT-based therapies, focusing on efficient delivery methods and rigorous clinical trials. Its competitive advantage lies in its proprietary formulations and experienced leadership.
Total Addressable Market (TAM)
The estimated TAM for depression and other mental health disorders is in the billions of dollars. GH Research PLC aims to capture a significant share of this market with its innovative therapies. Current projections range from $5B to $10B by 2030.
Upturn SWOT Analysis
Strengths
- Proprietary 5-MeO-DMT formulations
- Experienced leadership team
- Strong intellectual property portfolio
- Focus on efficient delivery methods
- Robust clinical trial design
Weaknesses
- High cash burn rate
- Reliance on successful clinical trial outcomes
- Regulatory hurdles
- Limited commercial infrastructure
- Concentrated product pipeline
Opportunities
- Expanding indications for 5-MeO-DMT
- Partnerships with pharmaceutical companies
- Positive clinical trial results
- Favorable regulatory changes
- Increasing awareness of mental health issues
Threats
- Clinical trial failures
- Regulatory rejection
- Competition from other psychedelic therapies
- Negative public perception
- Intellectual property infringement
Competitors and Market Share
Key Competitors
- CMPS
- ATAI
Competitive Landscape
GH Research faces competition from other companies developing psychedelic therapies. Its advantage lies in its focus on 5-MeO-DMT and efficient delivery methods, while its disadvantage is its reliance on a single molecule.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's early stage. Growth is primarily reflected in the expansion of its clinical trial programs.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approval. Analyst estimates vary widely, with some projecting significant revenue growth if GH001 is approved.
Recent Initiatives: Recent initiatives include enrolling patients in Phase 2b trials for GH001 in TRD and expanding research into other potential indications.
Summary
GH Research PLC is an early-stage biopharmaceutical company with a focus on innovative mental health treatments. It's in a high-risk, high-reward sector. The company has promising initial trials, but successful clinical trials and regulatory approval are vital. Its high cash burn rate and the need for more revenue sources pose significant challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Data is based on information available as of the current date and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GH Research PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-06-25 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 50 | Website https://www.ghres.com |
Full time employees 50 | Website https://www.ghres.com | ||
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.